Franco-Japanese pairing to promote Tenelia in China

28 February 2019

Tianjin Tanabe Seiyaku, a subsidiary of Japanese drug major Mitsubishi Tanabe Pharma (TYO: 4508), has teamed up with French independent drugmaker Servier Laboratories, to promote the type 2 diabetes drug Tenelia (teneligliptin).

China has the world’s largest population of people with type 2 diabetes and the number of diabetics is expected to increase from the current 130 million.

The collaboration with Servier, which has around 700 medical representatives in China specializing in diabetes and has a track record in sales going back 40 years, is expected to lead to the rapid market penetration of Tenelia and to the maximization of its value.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK